Phase 1 Clinical Trial for Anaplastic Large Cell Lymphoma: Zach Witt's Story
4,969 views · Published 30 May 2012 · 4:39 · Indexed 27 October 2026
Channel: The Children's Hospital of Philadelphia · 2012 · Science & Technology
When John and Pam Witt got the news that their son Zach's lymphoma had relapsed, they felt helpless and scared. But doctors at The Children's Hospital of Philadelphia were optimistic about an experimental treatment that they believed could save the 5-year-old's life. Zach's lymphoma is characterized by changes in the ALK gene. These changes in the make the lymphoma cells grow out of control. An ALK-inhibiting drug called crizotinib was developed to target the gene directly, which turns off that driving signal.
More from this channel
-
2:17
Importance of a Specialized Center for the Diagnosis and Treatment of Teratomas (10 of 10)
-
1:35
Short- and Long-term Outcomes for Children with Teratomas (9 of 10)
-
2:35
Before the Vaccine - Vaccines and Your Baby - The Children's Hospital of Philadelphia (2 of 14)
-
0:46
Can My Baby Get 4 or 5 Vaccines at a Time? - The Children's Hospital of Philadelphia (5 of 10)
-
0:34
Public Service Announcement - Youth Heart Watch - The Children's Hospital of Philadelphia (3 of 3)
-
6:36
Every Second Counts - Youth Heart Watch - The Children's Hospital of Philadelphia (2 of 3)
-
1:58
Why Choose a Specialized Center for Delivery of Babies with Large CCAM (8 of 10)
-
4:21
Evaluation - Scoliosis and Thoracic Insufficiency Syndrome (3 of 8)